JPMorgan analyst Jessica Fye lowered the firm’s price target on Novocure (NVCR) to $23 from $25 and keeps a Neutral rating on the shares. The firm updated the company’s model to reflect increased long-term conservatism.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVCR: